A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2016) John S. Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

(2015) Alan K. Burnett et al.   BLOOD

Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

(2015) Daniel A. Roberts et al.   LEUKEMIA RESEARCH

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

(2013) S. D. Gore et al.   HAEMATOLOGICA

Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients

(2012) Barbara Scappini et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

(2012) Stefan Faderl et al.   CANCER

Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

(2012) Stefan Faderl et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

(2011) Pamela S. Becker et al.   BRITISH JOURNAL OF HAEMATOLOGY

Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry

(2011) Gunnar Juliusson   Clinical Lymphoma Myeloma & Leukemia

A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly

(2011) Dimitrios C. Ziogas et al.   CLINICAL THERAPEUTICS

Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity

(2011) E. Agura et al.   ONCOLOGIST

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens

(2010) Samantha L. Price et al.   LEUKEMIA RESEARCH

Mechanisms of anti-cancer action and pharmacology of clofarabine

(2009) Anna Zhenchuk et al.   BIOCHEMICAL PHARMACOLOGY

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

(2009) John Koreth et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

(2008) S. Faderl et al.   BLOOD

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES